Stocks to Watch: Arcutis Biotherapeutics, Minerva Surgical, Enzo Biochem

Dow Jones2023-12-16

By Ben Glickman

Arcutis Biotherapeutics received FDA approval for its Zoryve topical foam in the treatment of seborrheic dermatitis late Friday. The company said it plans to make the product widely available by the end of next month. Shares gained 31% to $3.19 after-hours.

Minerva Surgical will delist its shares from the Nasdaq, with the last day of trading on or about Dec. 28. The women's health company expects the move to lower its general and administrative expenses. Shares fell 51% to $1.37 after-hours.

Enzo Biochem's revenue in the quarter ended Oct. 31 rose 10% as it saw higher demand in multiple product areas. The company's loss narrowed to $6.6 million, or 13 cents a share, from a loss of $10.6 million, or 22 cents a share, a year earlier. Shares rose 4.5% to $1.39 after-hours.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

December 15, 2023 18:27 ET (23:27 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2391105896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-12-16 07:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2391105896","market":"fut","top_or_hot":-1,"title":"Stocks to Watch: Arcutis Biotherapeutics, Minerva Surgical, Enzo Biochem","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Ben Glickman \n</p>\n<pre>\n \n</pre>\n<p>\n  Arcutis Biotherapeutics received FDA approval for its Zoryve topical foam in the treatment of seborrheic dermatitis late Friday. The company said it plans to make the product widely available by the end of next month. Shares gained 31% to $3.19 after-hours. \n</p>\n<p>\n  Minerva Surgical will delist its shares from the Nasdaq, with the last day of trading on or about Dec. 28. The women's health company expects the move to lower its general and administrative expenses. Shares fell 51% to $1.37 after-hours. \n</p>\n<p>\n  Enzo Biochem's revenue in the quarter ended Oct. 31 rose 10% as it saw higher demand in multiple product areas. The company's loss narrowed to $6.6 million, or 13 cents a share, from a loss of $10.6 million, or 22 cents a share, a year earlier. Shares rose 4.5% to $1.39 after-hours. \n</p>\n<pre>\n \n</pre>\n<p>\n   Write to Ben Glickman at ben.glickman@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2023 18:27 ET (23:27 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Arcutis Biotherapeutics, Minerva Surgical, Enzo Biochem</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Arcutis Biotherapeutics, Minerva Surgical, Enzo Biochem\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-16 07:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Ben Glickman \n\n\n \n\n\n  Arcutis Biotherapeutics received FDA approval for its Zoryve topical foam in the treatment of seborrheic dermatitis late Friday. The company said it plans to make the product ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2391105896","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2391105896","pubTimestamp":1702682820,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Arcutis Biotherapeutics received FDA approval for its Zoryve topical foam in the treatment of seborrheic dermatitis late Friday. The company said it plans to make the product widely available by the end of next month. Shares gained 31% to $3.19 after-hours.Minerva Surgical will delist its shares from the Nasdaq, with the last day of trading on or about Dec. 28. The women's health company expects the move to lower its general and administrative expenses. Shares fell 51% to $1.37 after-hours.Enzo Biochem's revenue in the quarter ended Oct. 31 rose 10% as it saw higher demand in multiple product areas. The company's loss narrowed to $6.6 million, or 13 cents a share, from a loss of $10.6 million, or 22 cents a share, a year earlier. Shares rose 4.5% to $1.39 after-hours.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","ARQT":"Arcutis Biotherapeutics Inc.","BK4082":"医疗保健设备","UTRS":"Minerva Surgical, Inc.","BK4139":"生物科技","ENZ":"恩佐生化"},"translate_title":"值得关注的股票：Arcutis Biotherapeutics、Minerva Surgical、Enzo Biochem","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENZ":1,"UTRS":1,"ARQT":0.9},"content_text":"By Ben Glickman \n\n\n \n\n\n  Arcutis Biotherapeutics received FDA approval for its Zoryve topical foam in the treatment of seborrheic dermatitis late Friday. The company said it plans to make the product widely available by the end of next month. Shares gained 31% to $3.19 after-hours. \n\n\n  Minerva Surgical will delist its shares from the Nasdaq, with the last day of trading on or about Dec. 28. The women's health company expects the move to lower its general and administrative expenses. Shares fell 51% to $1.37 after-hours. \n\n\n  Enzo Biochem's revenue in the quarter ended Oct. 31 rose 10% as it saw higher demand in multiple product areas. The company's loss narrowed to $6.6 million, or 13 cents a share, from a loss of $10.6 million, or 22 cents a share, a year earlier. Shares rose 4.5% to $1.39 after-hours. \n\n\n \n\n\n   Write to Ben Glickman at ben.glickman@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2023 18:27 ET (23:27 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2391105896"}